{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:56:07Z","timestamp":1781805367625,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40121-026-01362-z","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:12:22Z","timestamp":1780506742000},"page":"1955-1976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3339-7281","authenticated-orcid":false,"given":"Jinghao Nicholas","family":"Ngiam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enoch Xueheng","family":"Loy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew Chung Yi","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin J.","family":"Chiew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell Jingxian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Chi","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Shyong","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Mong","family":"Bee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Leng","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Chien Boon","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yew Woon","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Yan Yee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Hausenloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin Bryan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang En","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"16","key":"1362_CR1","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1001\/jama.2022.18931","volume":"328","author":"WS Hanson","year":"2022","unstructured":"Global Burden of Disease Long COVID Collaborators, Hanson WS, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604. https:\/\/doi.org\/10.1001\/jama.2022.18931.","journal-title":"JAMA"},{"issue":"9","key":"1362_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1093\/cid\/ciac961","volume":"76","author":"MM Robertson","year":"2023","unstructured":"Robertson MM, Qasmieh SA, Kulkarni SG, Teasdale CA, Jones HE, McNairy M, et al. The epidemiology of long coronavirus disease in US adults. Clin Infect Dis. 2023;76(9):1636\u201345. https:\/\/doi.org\/10.1093\/cid\/ciac961.","journal-title":"Clin Infect Dis"},{"key":"1362_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf030","author":"SM Bartsch","year":"2025","unstructured":"Bartsch SM, Chin KL, Strych U, John DC, Shah TD, Bottazzi ME, et al. The current and future burden of long COVID in the United States (U.S.). J Infect Dis. 2025. https:\/\/doi.org\/10.1093\/infdis\/jiaf030.","journal-title":"J Infect Dis"},{"key":"1362_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110202","volume":"195","author":"JL Harding","year":"2023","unstructured":"Harding JL, Oviedo SA, Ali MK, Ofotokun I, Gander JC, Patel SA, et al. The bidirectional association between diabetes and long-COVID-19\u2014a systematic review. Diabetes Res Clin Pract. 2023;195:110202. https:\/\/doi.org\/10.1016\/j.diabres.2022.110202.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"1362_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14986","volume":"40","author":"BM N\u00f8rg\u00e5rd","year":"2023","unstructured":"N\u00f8rg\u00e5rd BM, Zegers FD, Juhl CB, Kjeldsen J, Nielsen J. Diabetes mellitus and the risk of post\u2010acute COVID-19 hospitalizations\u2014a nationwide cohort study. Diabet Med. 2023;40(2):e14986. https:\/\/doi.org\/10.1111\/dme.14986.","journal-title":"Diabet Med"},{"issue":"1","key":"1362_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70437-z","volume":"14","author":"MC Nurchis","year":"2024","unstructured":"Nurchis MC, Raspolini GM, Heidar Alizadeh A, Garlasco J, Elhadidy HSMA, Gianino MM, et al. An ecological comparison to inspect the aftermath of post COVID-19 condition in Italy and the United States. Sci Rep. 2024;14(1):19407. https:\/\/doi.org\/10.1038\/s41598-024-70437-z.","journal-title":"Sci Rep"},{"issue":"1","key":"1362_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09601-6","volume":"23","author":"A Gandjour","year":"2023","unstructured":"Gandjour A. Long COVID: costs for the German economy and health care and pension system. BMC Health Serv Res. 2023;23(1):641. https:\/\/doi.org\/10.1186\/s12913-023-09601-6.","journal-title":"BMC Health Serv Res"},{"key":"1362_CR8","doi-asserted-by":"publisher","unstructured":"Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update. Circulation. 2019. https:\/\/doi.org\/10.1161\/CIR.0000000000000691.","DOI":"10.1161\/CIR.0000000000000691"},{"issue":"1","key":"1362_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.13854","volume":"22","author":"RJ Chilton","year":"2020","unstructured":"Chilton RJ. Effects of sodium\u2010glucose cotransporter\u20102 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diabetes Obes Metab. 2020;22(1):16\u201329. https:\/\/doi.org\/10.1111\/dom.13854.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1362_CR10","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1136\/gutjnl-2024-332481","volume":"73","author":"X Mao","year":"2024","unstructured":"Mao X, Zhang X, Kam L, Chien N, Lai R, Cheung KS, et al. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Gut. 2024;73(12):2054\u201361. https:\/\/doi.org\/10.1136\/gutjnl-2024-332481.","journal-title":"Gut"},{"issue":"1","key":"1362_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49525-y","volume":"9","author":"JH Bae","year":"2019","unstructured":"Bae JH, Park EG, Kim S, Kim SG, Hahn S, Kim NH. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):13009. https:\/\/doi.org\/10.1038\/s41598-019-49525-y.","journal-title":"Sci Rep"},{"issue":"2","key":"1362_CR12","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/jcp.30621","volume":"237","author":"S Ravindran","year":"2022","unstructured":"Ravindran S, Munusamy S. Renoprotective mechanisms of sodium\u2010glucose co\u2010transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. J Cell Physiol. 2022;237(2):1182\u2013205. https:\/\/doi.org\/10.1002\/jcp.30621.","journal-title":"J Cell Physiol"},{"issue":"3","key":"1362_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/03007995.2022.2027141","volume":"38","author":"A Alshnbari","year":"2022","unstructured":"Alshnbari A, Idris I. Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19?\u2014targeting hyperinflammation. Curr Med Res Opin. 2022;38(3):357\u201364. https:\/\/doi.org\/10.1080\/03007995.2022.2027141.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"1362_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072030","volume":"9","author":"B Fernandez-Fernandez","year":"2020","unstructured":"Fernandez-Fernandez B, D\u2019Marco L, G\u00f3rriz JL, Jacobs-Cach\u00e1 C, Kanbay M, Luis-Lima S, et al. Exploring sodium glucose co-transporter-2 (SGLT2) inhibitors for organ protection in COVID-19. JCM. 2020;9(7):2030. https:\/\/doi.org\/10.3390\/jcm9072030.","journal-title":"JCM"},{"issue":"8","key":"1362_CR15","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/iub.2719","volume":"75","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi H, Maleki M, Atkin SL, Kesharwani P, Jamialahmadi T, Sahebkar A. Anti\u2010inflammatory effects of sodium\u2010glucose cotransporter\u20102 inhibitors in COVID\u201019. IUBMB Life. 2023;75(8):648\u201358. https:\/\/doi.org\/10.1002\/iub.2719.","journal-title":"IUBMB Life"},{"key":"1362_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02056","volume":"11","author":"X Chen","year":"2020","unstructured":"Chen X, Guo H, Qiu L, Zhang C, Deng Q, Leng Q. Immunomodulatory and antiviral activity of metformin and its potential implications in treating coronavirus disease 2019 and lung injury. Front Immunol. 2020;11:2056. https:\/\/doi.org\/10.3389\/fimmu.2020.02056.","journal-title":"Front Immunol"},{"issue":"7","key":"1362_CR17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","volume":"54","author":"H Xian","year":"2021","unstructured":"Xian H, Liu Y, Rundberg Nilsson A, Gatchalian R, Crother TR, Tourtellotte WG, et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54(7):1463-1477.e11. https:\/\/doi.org\/10.1016\/j.immuni.2021.05.004.","journal-title":"Immunity"},{"key":"1362_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733921","volume":"12","author":"TJ Cory","year":"2021","unstructured":"Cory TJ, Emmons RS, Yarbro JR, Davis KL, Pence BD. Metformin suppresses monocyte immunometabolic activation by SARS-CoV-2 spike protein subunit 1. Front Immunol. 2021;12:733921. https:\/\/doi.org\/10.3389\/fimmu.2021.733921.","journal-title":"Front Immunol"},{"issue":"6","key":"1362_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009634","volume":"17","author":"E Varghese","year":"2021","unstructured":"Varghese E, Samuel SM, Liskova A, Kubatka P, B\u00fcsselberg D. Diabetes and coronavirus (SARS-CoV-2): molecular mechanism of metformin intervention and the scientific basis of drug repurposing. PLoS Pathog. 2021;17(6):e1009634. https:\/\/doi.org\/10.1371\/journal.ppat.1009634.","journal-title":"PLoS Pathog"},{"issue":"12","key":"1362_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/v16121938","volume":"16","author":"I Halabitska","year":"2024","unstructured":"Halabitska I, Petakh P, Lushchak O, Kamyshna I, Oksenych V, Kamyshnyi O. Metformin in antiviral therapy: evidence and perspectives. Viruses. 2024;16(12):1938. https:\/\/doi.org\/10.3390\/v16121938.","journal-title":"Viruses"},{"issue":"10","key":"1362_CR21","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S1473-3099(23)00299-2","volume":"23","author":"CT Bramante","year":"2023","unstructured":"Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23(10):1119\u201329. https:\/\/doi.org\/10.1016\/S1473-3099(23)00299-2.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1362_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020431","volume":"13","author":"KR Lim","year":"2024","unstructured":"Lim KR, Chun KJ, Kim BS, Lee S. The effect of sodium\u2013glucose cotransporter-2 inhibitors on COVID-19 patients with type 2 diabetes mellitus: a retrospective cohort study using the common data model. JCM. 2024;13(2):431. https:\/\/doi.org\/10.3390\/jcm13020431.","journal-title":"JCM"},{"issue":"11","key":"1362_CR23","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.2337\/dca24-0032","volume":"47","author":"SG Johnson","year":"2024","unstructured":"Johnson SG, Abedian S, St\u00fcrmer T, Huling JD, Lewis VC, Buse JB, et al. Prevalent metformin use in adults with diabetes and the incidence of long COVID: an EHR-based cohort study from the RECOVER program. Diabetes Care. 2024;47(11):1930\u201340. https:\/\/doi.org\/10.2337\/dca24-0032.","journal-title":"Diabetes Care"},{"issue":"1","key":"1362_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-03054-5","volume":"23","author":"HW Yeh","year":"2025","unstructured":"Yeh HW, Chaou CH, Yang SF, Wang YH, Kuan YH, Yeh CB. SGLT2 inhibitors prevent long-COVID-associated cognitive and pain symptoms in type 2 diabetes patients. Virol J. 2025;23(1):27. https:\/\/doi.org\/10.1186\/s12985-025-03054-5.","journal-title":"Virol J"},{"issue":"3","key":"1362_CR25","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1093\/cid\/ciaf429","volume":"82","author":"U Chaichana","year":"2026","unstructured":"Chaichana U, Man KKC, Ju C, Makaronidis J, Wei L. Effect of metformin on the risk of Post-COVID-19 condition among individuals with overweight or obese: a population-based retrospective cohort study. Clin Infect Dis. 2026;82(3):e423\u201332. https:\/\/doi.org\/10.1093\/cid\/ciaf429.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"1362_CR26","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.cmi.2023.06.016","volume":"29","author":"LE Wee","year":"2023","unstructured":"Wee LE, Tay AT, Chiew C, Young BE, Wong B, Lim R, et al. Real-world effectiveness of nirmatrelvir\/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4\/5, and XBB transmission. Clin Microbiol Infect. 2023;29(10):1328\u201333. https:\/\/doi.org\/10.1016\/j.cmi.2023.06.016.","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"1362_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.30983","volume":"7","author":"LE Wee","year":"2024","unstructured":"Wee LE, Lim JT, Tay AT, Chiew CJ, Ong B, Lye DCB, et al. Autoimmune sequelae after Delta or Omicron variant SARS-CoV-2 infection in a highly vaccinated cohort. JAMA Netw Open. 2024;7(8):e2430983. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.30983.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1362_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/cid\/ciad469","volume":"78","author":"JT Lim","year":"2024","unstructured":"Lim JT, Liang En W, Tay AT, Pang D, Chiew CJ, Ong B, et al. Long-term cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors: a retrospective cohort study. Clin Infect Dis. 2024;78(1):70\u20139. https:\/\/doi.org\/10.1093\/cid\/ciad469.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1362_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cmi.2023.12.019","volume":"30","author":"LE Wee","year":"2024","unstructured":"Wee LE, Lim JT, Tay AT, Pang D, Dickens B, Chiew CJ, et al. Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infection. Clin Microbiol Infect. 2024;30(4):531\u20139. https:\/\/doi.org\/10.1016\/j.cmi.2023.12.019.","journal-title":"Clin Microbiol Infect"},{"key":"1362_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.08.019","author":"LE Wee","year":"2024","unstructured":"Wee LE, Lim JT, Tay AT, Chiew CJ, Young BE, Wong B, et al. Nirmatrelvir\/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans. Clin Microbiol Infect. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2024.08.019.","journal-title":"Clin Microbiol Infect"},{"issue":"10305","key":"1362_CR31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-673(21)00252-X","volume":"398","author":"CC Tan","year":"2021","unstructured":"Tan CC, Lam CSP, Matchar DB, Zee YK, Wong JEL. Singapore\u2019s health-care system: key features, challenges, and shifts. Lancet. 2021;398(10305):1091\u2013104. https:\/\/doi.org\/10.1016\/S0140-673(21)00252-X.","journal-title":"Lancet"},{"issue":"1","key":"1362_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010755","volume":"24","author":"I Nojima","year":"2023","unstructured":"Nojima I, Wada J. Metformin and its immune-mediated effects in various diseases. Int J Mol Sci. 2023;24(1):755. https:\/\/doi.org\/10.3390\/ijms24010755.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1362_CR33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.tim.2021.03.004","volume":"29","author":"SM Samuel","year":"2021","unstructured":"Samuel SM, Varghese E, B\u00fcsselberg D. Therapeutic potential of metformin in COVID-19: reasoning for its protective role. Trends Microbiol. 2021;29(10):894\u2013907. https:\/\/doi.org\/10.1016\/j.tim.2021.03.004.","journal-title":"Trends Microbiol"},{"key":"1362_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645194","volume":"12","author":"M Zangiabadian","year":"2021","unstructured":"Zangiabadian M, Nejadghaderi SA, Zahmatkesh MM, Hajikhani B, Mirsaeidi M, Nasiri MJ. The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: a systematic review. Front Endocrinol. 2021;12:645194. https:\/\/doi.org\/10.3389\/fendo.2021.645194.","journal-title":"Front Endocrinol"},{"issue":"10","key":"1362_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105190","volume":"25","author":"TJ Plowman","year":"2024","unstructured":"Plowman TJ, Christensen H, Aiges M, Fernandez E, Shah MH, Ramana KV. Anti-inflammatory potential of the anti-diabetic drug metformin in the prevention of inflammatory complications and infectious diseases including COVID-19: a narrative review. Int J Mol Sci. 2024;25(10):5190. https:\/\/doi.org\/10.3390\/ijms25105190.","journal-title":"Int J Mol Sci"},{"key":"1362_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2022.199010","volume":"323","author":"H Parthasarathy","year":"2023","unstructured":"Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res. 2023;323:199010. https:\/\/doi.org\/10.1016\/j.virusres.2022.199010.","journal-title":"Virus Res"},{"issue":"2","key":"1362_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/cid\/ciae159","volume":"79","author":"CT Bramante","year":"2024","unstructured":"Bramante CT, Beckman KB, Mehta T, Karger AB, Odde DJ, Tignanelli CJ, et al. Favorable antiviral effect of metformin on SARS-CoV-2 viral load in a randomized, placebo-controlled clinical trial of COVID-19. Clin Infect Dis. 2024;79(2):354\u201363. https:\/\/doi.org\/10.1093\/cid\/ciae159.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1362_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/v16020281","volume":"16","author":"P Petakh","year":"2024","unstructured":"Petakh P, Kamyshna I, Oksenych V, Kamyshnyi O. Metformin alters mRNA expression of FOXP3, RORC, and TBX21 and modulates gut microbiota in COVID-19 patients with Type 2 diabetes. Viruses. 2024;16(2):281. https:\/\/doi.org\/10.3390\/v16020281.","journal-title":"Viruses"},{"key":"1362_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/0109298673289342240213040144","volume":"21","author":"P Shivaprakash","year":"2024","unstructured":"Shivaprakash P, Beeraka NM, Madhunapantula SRV, Nikolenko VN, Basalingappa KM. Metformin effects on SHIP2, AMPKs and gut microbiota: recent updates on pharmacology. CMC. 2024;21:31. https:\/\/doi.org\/10.2174\/0109298673289342240213040144.","journal-title":"CMC"},{"issue":"12","key":"1362_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44652","volume":"5","author":"Z Zhu","year":"2022","unstructured":"Zhu Z, Zeng Q, Liu Q, Wen J, Chen G. Association of glucose-lowering drugs with outcomes in patients with diabetes before hospitalization for COVID-19: a systematic review and network meta-analysis. JAMA Netw Open. 2022;5(12):e2244652. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.44652.","journal-title":"JAMA Netw Open"},{"key":"1362_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110205","volume":"195","author":"H Permana","year":"2023","unstructured":"Permana H, Audi Yanto T, Ivan Hariyanto T. Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract. 2023;195:110205. https:\/\/doi.org\/10.1016\/j.diabres.2022.110205.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1362_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.tem.2024.02.003","volume":"35","author":"M Mashayekhi","year":"2024","unstructured":"Mashayekhi M, Safa BI, Gonzalez MSC, Kim SF, Echouffo-Tcheugui JB. Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors. Trends Endocrinol Metab. 2024;35(5):425\u201338. https:\/\/doi.org\/10.1016\/j.tem.2024.02.003.","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"1362_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105634","volume":"23","author":"S Feij\u00f3o-Band\u00edn","year":"2022","unstructured":"Feij\u00f3o-Band\u00edn S, Arag\u00f3n-Herrera A, Otero-Santiago M, Anido-Varela L, Mora\u00f1a-Fern\u00e1ndez S, Taraz\u00f3n E, et al. Role of sodium-glucose co-transporter 2 inhibitors in the regulation of inflammatory processes in animal models. IJMS. 2022;23(10):5634. https:\/\/doi.org\/10.3390\/ijms23105634.","journal-title":"IJMS"},{"issue":"17","key":"1362_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20176671","volume":"20","author":"E Sch\u00f6nberger","year":"2023","unstructured":"Sch\u00f6nberger E, Mihaljevi\u0107 V, Steiner K, \u0160ari\u0107 S, Kurevija T, Majnari\u0107 LT, et al. Immunomodulatory effects of SGLT2 inhibitors\u2014targeting inflammation and oxidative stress in aging. IJERPH. 2023;20(17):6671. https:\/\/doi.org\/10.3390\/ijerph20176671.","journal-title":"IJERPH"},{"issue":"4","key":"1362_CR45","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/dom.13577","volume":"21","author":"JH Kim","year":"2019","unstructured":"Kim JH, Lee M, Kim SH, Kim SR, Lee B, Kang ES, et al. Sodium\u2010glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter\u2010organ crosstalk. Diabetes Obes Metab. 2019;21(4):801\u201311. https:\/\/doi.org\/10.1111\/dom.13577.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1362_CR46","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/jcb.30327","volume":"123","author":"H Yaribeygi","year":"2022","unstructured":"Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A. New insights into cellular links between sodium\u2013glucose cotransporter\u20102 inhibitors and ketogenesis. J Cell Biochem. 2022;123(12):1879\u201390. https:\/\/doi.org\/10.1002\/jcb.30327.","journal-title":"J Cell Biochem"},{"issue":"7","key":"1362_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076039","volume":"24","author":"ME Youssef","year":"2023","unstructured":"Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control. Int J Mol Sci. 2023;24(7):6039. https:\/\/doi.org\/10.3390\/ijms24076039.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1362_CR48","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqab157","volume":"162","author":"M Ala","year":"2021","unstructured":"Ala M. SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD. Endocrinology. 2021;162(12):bqab157. https:\/\/doi.org\/10.1210\/endocr\/bqab157.","journal-title":"Endocrinology"},{"issue":"23","key":"1362_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237213","volume":"26","author":"A Pawlos","year":"2021","unstructured":"Pawlos A, Broncel M, Wo\u017aniak E, Gorzelak-Pabi\u015b P. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021;26(23):7213. https:\/\/doi.org\/10.3390\/molecules26237213.","journal-title":"Molecules"},{"issue":"4","key":"1362_CR50","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. J Am Coll Cardiol. 2020;75(4):422\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1362_CR51","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s11096-021-01256-9","volume":"43","author":"T Koufakis","year":"2021","unstructured":"Koufakis T, Pavlidis AN, Metallidis S, Kotsa K. Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases. Int J Clin Pharm. 2021;43(3):764\u20137. https:\/\/doi.org\/10.1007\/s11096-021-01256-9.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"1362_CR52","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41591-024-02987-8","volume":"30","author":"M Cai","year":"2024","unstructured":"Cai M, Xie Y, Topol EJ, Al-Aly Z. Three-year outcomes of post-acute sequelae of COVID-19. Nat Med. 2024;30(6):1564\u201373. https:\/\/doi.org\/10.1038\/s41591-024-02987-8.","journal-title":"Nat Med"},{"issue":"9","key":"1362_CR53","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/s41591-023-02521-2","volume":"29","author":"B Bowe","year":"2023","unstructured":"Bowe B, Xie Y, Al-Aly Z. Postacute sequelae of COVID-19 at 2 years. Nat Med. 2023;29(9):2347\u201357. https:\/\/doi.org\/10.1038\/s41591-023-02521-2.","journal-title":"Nat Med"},{"issue":"27","key":"1362_CR54","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007201","volume":"96","author":"J Li","year":"2017","unstructured":"Li J, Gong Y, Li C, Lu Y, Liu Y, Shao Y. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: a meta-analysis. Medicine. 2017;96(27):e7201. https:\/\/doi.org\/10.1097\/MD.0000000000007201.","journal-title":"Medicine"},{"issue":"3","key":"1362_CR55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.diabres.2014.06.006","volume":"105","author":"Q Zhang","year":"2014","unstructured":"Zhang Q, Dou J, Lu J. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract. 2014;105(3):313\u201321. https:\/\/doi.org\/10.1016\/j.diabres.2014.06.006.","journal-title":"Diabetes Res Clin Pract"},{"key":"1362_CR56","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ijid.2020.11.157","volume":"103","author":"JN Ngiam","year":"2021","unstructured":"Ngiam JN, Chew N, Tham SM, Beh DLL, Lim ZY, Li TYW, et al. Demographic shift in COVID-19 patients in Singapore from an aged, at-risk population to young migrant workers with reduced risk of severe disease. Int J Infect Dis. 2021;103:329\u201335. https:\/\/doi.org\/10.1016\/j.ijid.2020.11.157.","journal-title":"Int J Infect Dis"},{"key":"1362_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ijid.2022.12.007","volume":"127","author":"JN Ngiam","year":"2023","unstructured":"Ngiam JN, Chhabra S, Goh W, Sim MY, Chew NW, Sia CH, et al. Continued demographic shifts in hospitalised patients with COVID-19 from migrant workers to a vulnerable and more elderly local population at risk of severe disease. Int J Infect Dis. 2023;127:77\u201384. https:\/\/doi.org\/10.1016\/j.ijid.2022.12.007.","journal-title":"Int J Infect Dis"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01362-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01362-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:33:09Z","timestamp":1781803989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01362-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1362"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01362-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors [Jinghao Nicholas Ngiam, Enoch Xueheng Loy, Matthew Chung Yi Koh, Calvin J Chiew, Russell Jingxian Li, Su Chi Lim, E Shyong Tai, Yong Mong Bee, Wai Leng Chow, David Chien Boon Lye, Yew Woon Chia, Mark Yan Yee Chan, Derek J Hausenloy, Kelvin Bryan Tan, Liang En Wee] report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted as part of national public health surveillance under the Singapore Infectious Diseases Act, and separate ethics approval by an Institutional Review Board (IRB) was not required. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}